Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells
Mayara Garcia de Mattos Barbosa, Adam R. Lefferts, Daniel Huynh, Hui Liu, Yu Zhang, Beverly Fu, Jenna Barnes, Milagros Samaniego, Richard J. Bram, Raif S. Geha, Ariella Shikanov, Eline T. Luning Prak, Evan A. Farkash, Jeffrey L. Platt, Marilia Cascalho
Mayara Garcia de Mattos Barbosa, Adam R. Lefferts, Daniel Huynh, Hui Liu, Yu Zhang, Beverly Fu, Jenna Barnes, Milagros Samaniego, Richard J. Bram, Raif S. Geha, Ariella Shikanov, Eline T. Luning Prak, Evan A. Farkash, Jeffrey L. Platt, Marilia Cascalho
View: Text | PDF
Research Article Genetics Inflammation

TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells

  • Text
  • PDF
Abstract

Host genes define the severity of inflammation and immunity but specific loci doing so are unknown. Here we show that TNF receptor superfamily member 13B (TNFRSF13B) variants, which enhance defense against certain pathogens, also control immune-mediated injury of transplants, by regulating innate B cells’ functions. Analysis of TNFRSF13B in human kidney transplant recipients revealed that 33% of those with antibody-mediated rejection (AMR) but fewer than 6% of those with stable graft function had TNFRSF13B missense mutations. To explore mechanisms underlying aggressive immune responses, we investigated alloimmunity and rejection in mice. Cardiac allografts in Tnfrsf13b-mutant mice underwent early and severe AMR. The dominance and precocity of AMR in Tnfrsf13b-deficient mice were not caused by increased alloantibodies. Rather, Tnfrsf13b mutations decreased “natural” IgM and compromised complement regulation, leading to complement deposition in allografted hearts and autogenous kidneys. Thus, WT TNFRSF13B and Tnfrsf13b support innate B cell functions that limit complement-associated inflammation; in contrast, common variants of these genes intensify inflammatory responses that help clear microbial infections but allow inadvertent tissue injury to ensue. The wide variation in inflammatory reactions associated with TNFRSF13B diversity suggests polymorphisms could underlie variation in host defense and explosive inflammatory responses that sometimes enhance morbidity associated with immune responses.

Authors

Mayara Garcia de Mattos Barbosa, Adam R. Lefferts, Daniel Huynh, Hui Liu, Yu Zhang, Beverly Fu, Jenna Barnes, Milagros Samaniego, Richard J. Bram, Raif S. Geha, Ariella Shikanov, Eline T. Luning Prak, Evan A. Farkash, Jeffrey L. Platt, Marilia Cascalho

×

Figure 1

Tnfrsf13b deficiency evokes antibody responses to allografts and accelerates rejection of heart allografts.

Options: View larger image (or click on image) Download as PowerPoint

Tnfrsf13b deficiency evokes antibody responses to allografts and accele...
Hearts (transplanted heterotopically into the abdomen) and skin from CB6F1 mice (C57BL/6-BALB/c F1, H-2b/d haplotype) were transplanted into C57BL/6 (H-2b/b haplotype) WT and Tnfrsf13b-KO mice, and allograft survival was evaluated daily until rejection. (A) Graph represents the mean ± SEM of the number of days elapsed until allograft rejection (n = 14). See also Table 2. (B) H&E staining and anti-IgG, anti-C3d, anti-CD4, anti-CD8, and anti-Foxp3 (to detect T regulatory cells) immunostainings. Images are representative of a mouse of each group with viable heart excision at day 14 (H&E, C3d and IgG staining) or at rejection at day 19 (CD4, CD8, and Foxp3 staining). See also Supplemental Figure 1. Scale bar: 25 μm. (C) Graph depicts the number of CD4+, CD8+ of Foxp3+ (Tregs) T cells per mm2 in sections counted in 5 nonoverlapping fields obtained from grafts at rejection. (D) Graph represents the relationship between number of CD4+ T cells in graft sections and length of transplantation. Statistical analysis (Pearson correlation P = 0.0024) indicates that the number of CD4+ T cells/mm2 increases with time from transplantation. (E) Sera of recipient mice were collected before transplantation (day 0, D0) and at time of rejection, and allospecific IgM and IgG were analyzed by flow cytometry. Graphs are representative of mean ± SEM of 7–9 mice per group. One-tailed unpaired t test (A), 2-tailed unpaired t test (C), or 2-tailed paired and unpaired t tests or Mann-Whitney test (E): *P ≤ 0.05, **P ≤ 0.01 in relation to WT control; ###P ≤ 0.001 in relation to day 0 (D0).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts